Angiographic and clinical outomes of bivalirudin versus heparin in patients with acute coronary syndrome undergoing percutaneous coronary intervention

Canadian Journal of Cardiology

Volumn 22, Issue 13, 2006, Pages 1139-1145

  Matar, Fadi ^a   Donoghue, Colleen ^a   Rossi, Peter ^a   Vandormael, Michel ^a   Sullebarger, John T ^a   Kerensky, Richard ^a   Jauch, Werner ^a   Gloer, Kathy ^a   Ebra, George ^a  

^a Florida Cardiovascular Institute   (United States)

Author keywords

Angioplasty; Anticoagulants; Bivalirudin; Heparin; Myocardial infarction; Stents

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; CONTROLLED STUDY; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT OUTCOME; ACUTE DISEASE; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DRUG ANTAGONISM; DRUG COMBINATION; FEMALE; FOLLOW UP; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; RISK FACTOR; SYNDROME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ACUTE DISEASE; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HIRUDINS; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECOMBINANT PROTEINS; RISK FACTORS; SYNDROME; TREATMENT OUTCOME;

EID: 33845582022     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0828-282X(06)70951-5     Document Type: Article

References (21)

1. Sobel M, Fish WR, Toma N, et al. Heparin modulates integrin function in human platelets. J Vasc Surg 2001;33:587-94.
2. Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol 2002;22:1381-9.
3. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-6.
4. Topol EJ, Califf RM, Weisman HF, et al; the EPIC Investigators. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: Results at six months. Lancet 1994;343:881-6.
5. Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: Results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Lancet 1999;354:2019-24.
6. Zwart-van Rijkom JE, van Hour BA. Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/ IIIa Inhibitor For Stenting Trial. Eur Heart J 2001;22:1476-84.
7. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-9.
8. Lincoff AM, Bittl JA, Harrington RA, et al; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.
9. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study. Lancet 1997;349:1429-35.
10. Wilson JM, Dougherty KG, Ellis KO, Ferguson JJ. Activated clotting times in acute coronary syndromes and percutaneous transluminal coronary angioplasty. Cathet Cardiovasc Diagn 1995;34:1-5.
11. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable and non-Q-wave myocardial infarcrion. N Engl J Med 1998;338:1488-97.
12. Zhao XQ, Theroux P, Snapinn SM, Sax FL. Intracoronary thrombus and platelet glycoprotein IIb/IIIa receptor blockade with tirofiban in unstable angina or non-Q-wave myocardial infarction. Angiographic results from the PRISM-PLUS trial (Platelet receptor inhibition for ischemic syndrome management in patients limited by unstable signs and symptoms). PRISM-PLUS Investigators. Circulation 1999;100:1609-15.
13. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. The PURSUIT Trial Investigators, N Engl J Med 1998;339:436-43.
14. Singh M, Reeder GS, Ohman EM, et al. Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An Angiographic Trials Pool data experience. J Am Coll Cardiol 2001;38:624-30.
15. Aggarwal A, Sobel BE, Schneider DJ. Decreased platelet reactivity in blood anticoagulated with bivalirudin or enoxaparin compared with unfractionated heparin: Implications for coronary intervention. J Thromb Thrombolysis 2002;13:161-5.
16. Furman MI, Kereiakes DJ, Krueger LA, et al. Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab. Am Heart J 2001;142:790-8.
17. Mann KG, Butenas S, Brummel K. The dynamics of thrombin formation. Arterioscler Thromb Vasc Biol 2003;23:17-25.
18. Wittkowsky AK. The rote of thrombin inhibition during percutaneous coronary intervention. Pharmacotherapy 2002;22:97S-104S.
19. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998;352:87-92.
20. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutancous coronary revascularization. N Engl J Med 1997;336:1689-96.
21. Cohen DJ, Lincoff AM, Lavelle TA, et al. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: Results from the REPLACE-2 trial. J Am Coll Cardiol 2004;44:1792-800.